The addition of the PCSK9 inhibitor alirocumab to high-intensity statin therapy after acute myocardial infarction (AMI) led to significantly greater coronary plaque regression in non-infarct-related arteries after 52 weeks after percutaneous coronary intervention (PCI) as compared to placebo, according to new trial data.